Novartis Builds Radioligand Therapy Site in Texas

Novartis announced on February 25 it will build a 46,000-square-foot radioligand therapy (RLT) manufacturing site in Denton, Texas, with construction starting in 2026 and full operations expected in 2028. The facility, the company’s fifth U.S. RLT site and first in Texas as part of a $23 billion U.S. investment, is expected to create advanced manufacturing and bioengineering jobs and expand cancer-treatment capacity.